Call for Abstracts: DIA EuroMeeting 2017

DIA29 - 31 March 2017, Glasgow, UK.
The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and access process to debate and find solutions to some of the most pertinent challenges faced in an ever-evolving healthcare system - including the need to drive innovation.

DIA invites you to submit presentation, session and tutorial abstracts for the 29th Annual EuroMeeting in Glasgow, UK. You may submit more than one abstract. Abstracts should fall under one of the themes detailed bellow.

Session Abstract
A session abstract is a 90-minute session concept delivered lecture-style from the podium. The abstract author is considered the session chair and will coordinate efforts in recruiting speakers and managing the session (including the facilitation of question and answers from the audience). PowerPoint presentations are required. We encourage innovative ideas for session formats that will enhance interaction between stakeholders.

Presentation Abstract
A presentation abstract is for a 20-minute presentation in a specific topic area; the abstract author is considered the speaker. A PowerPoint presentation is required. If selected, the abstract will consist of a single presentation which will fit within a session.

Tutorial Abstract
A tutorial is a 'hands-on', interactive learning experience. A tutorial consists of 3 hours of instruction with a 30-minute break. The abstract author is considered the instructor. One co-instructor may be recruited but cannot be from the same company/organisation as the author.

Hot-Topic / Stand-Alone Sessions
Each year, there are a number of sessions which do not fit directly under the programme themes. If your abstract clearly does not fit with any of the themes / topics outlined, you may submit it for consideration as a hot-topic / stand-alone presentation or session.

How to maximise the probability of your abstract being accepted
Abstracts will be selected by the EuroMeeting Programme Committee. The theme leaders have indicated the strategic topics they would like to address.

  • Focus your abstracts on the proposed topics in this flyer. If your abstract clearly does not fit, submit it as a hot topic / stand-alone presentation or session
  • Your abstract should be as clear and as detailed as possible to enable the theme leaders to make a judgement on its suitability for the programme
  • Abstracts must be non-promotional and non-commercial in order to be considered

If you have any questions about abstract submission, please email the EuroMeeting team: This email address is being protected from spambots. You need JavaScript enabled to view it.

The deadline for submitting abstracts is Monday, 27 June 2016.

For further information, please visit:
http://www.diaglobal.org/en/conference-listing/meetings/2017/03/29th-annual-euromeeting

About DIA
For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.

DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, the Middle East, and Africa (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan).

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...